New drug regimen for multidrug-resistant tuberculosis shows early effectiveness in 85 percent of patients in a cohort including many with serious comorbidities. The results suggest a global need for expanded access to two recently developed medicines, bedaquiline and delamanid. Study cohort included many people who would have been excluded from trials because of comorbidities, severity of disease or extent of drug resistance. Findings highlight the importance of innovative regimens to improve outcomes for patients with multidrug-resistant tuberculosis.
- The male Y chromosome does more than we thought
- Ultrapotent compound may help treat C. diff, reduce recurrence
- High-performance single-atom catalysts for high-temperature fuel cells
- Novel neuroimaging study on dissociative symptoms reveals wounds of childhood trauma
- Historical racial & ethnic health inequities account for disproportionate COVID-19 impact